Table 1 Open in new tab Baseline...

Characteristic	TCS (n = 173)	NB‐UVB (n = 169)	Combination (n = 175)
Age at randomization (years), mean (SD)	38·6 (20·0)	36·9 (18·9)	37·0 (19·1)
Age of adults at randomization (years), mean (SD); n	46·7 (15·2); 133	44·7 (14·0); 130	44·8 (14·2); 135
Age of children at randomization (years), mean (SD); n	11·7 (3·7); 40	10·8 (3·5); 39	10·6 (3·3); 40
Sex male	75 (43)	88 (52)	105 (60)
Ethnicity
White	112 (65)	114 (67)	104 (59)
Indian	13 (8)	13 (8)	10 (6)
Pakistani	12 (7)	15 (9)	27 (15)
Bangladeshi	4 (2)	4 (2)	4 (2)
Black	5 (3)	3 (2)	7 (4)
Chinese	2 (1)	1 (1)	1 (1)
Other Asian (not Chinese)	5 (3)	6 (4)	6 (3)
Mixed race	9 (5)	6 (4)	6 (3)
Other	10 (6)	7 (4)	9 (5)
Missing	1 (1)	0	1 (1)
Source of recruitment
Primary care	35 (20)	36 (21)	47 (27)
Secondary care	74 (43)	67 (40)	72 (41)
Self‐referral	64 (37)	66 (39)	56 (32)
Skin phototype
I	2 (1)	2 (1)	5 (3)
II	31 (18)	32 (19)	29 (17)
III	70 (40)	66 (39)	59 (34)
IV	29 (17)	34 (20)	33 (19)
V	35 (20)	25 (15)	44 (25)
VI	6 (3)	10 (6)	5 (3)
Medical history
Type I diabetes	5 (3)	3 (2)	4 (2)
Hyperthyroidism	4 (2)	2 (1)	6 (3)
Hypothyroidism	21 (12)	18 (11)	10 (6)
Addison disease	2 (1)	0	3 (2)
Pernicious anaemia	5 (3)	3 (2)	6 (3)
Alopecia areata	3 (2)	7 (4)	3 (2)
Duration of vitiligo (years), median (interquartile range)	7 (3–16)	5 (3–11)	7 (4–15)
Previous treatments used for vitiligo
Light therapy	28 (16)	26 (15)	37 (21)
Corticosteroid cream or ointment	80 (46)	75 (44)	80 (46)
Calcineurin inhibitor cream or ointment	51 (29)	39 (23)	56 (32)
Cosmetic camouflage	45 (26)	44 (26)	40 (23)
Other	20 (12)	15 (9)	17 (10)
Target patch location
Head and neck	53 (31)	52 (31)	56 (32)
Hands and feet	56 (32)	53 (31)	55 (31)
Rest of the body	64 (37)	64 (38)	64 (37)
Number of assessed patches
1	50 (29)	50 (30)	62 (35)
2	74 (43)	77 (46)	73 (42)
3	49 (28)	42 (25)	40 (23)
Target patch hypomelanotic^a
Definitely	52 (30)	46 (27)	52 (30)
Maybe or no	121 (70)	123 (73)	123 (70)

Characteristic

TCS (n = 173)

NB‐UVB (n = 169)

Combination (n = 175)

Age at randomization (years), mean (SD)

38·6 (20·0)

36·9 (18·9)

37·0 (19·1)

Age of adults at randomization (years), mean (SD); n

46·7 (15·2); 133

44·7 (14·0); 130

44·8 (14·2); 135

Age of children at randomization (years), mean (SD); n

11·7 (3·7); 40

10·8 (3·5); 39

10·6 (3·3); 40

Sex male

75 (43)

88 (52)

105 (60)

Ethnicity

White

112 (65)

114 (67)

104 (59)

Indian

13 (8)

10 (6)

Pakistani

12 (7)

15 (9)

27 (15)

Bangladeshi

4 (2)

Black

5 (3)

3 (2)

7 (4)

Chinese

2 (1)

1 (1)

Other Asian (not Chinese)

5 (3)

6 (4)

6 (3)

Mixed race

9 (5)

6 (4)

6 (3)

Other

10 (6)

7 (4)

9 (5)

Missing

1 (1)

Source of recruitment

Primary care

35 (20)

36 (21)

47 (27)

Secondary care

74 (43)

67 (40)

72 (41)

Self‐referral

64 (37)

66 (39)

56 (32)

Skin phototype

2 (1)

5 (3)

31 (18)

32 (19)

29 (17)

III

70 (40)

66 (39)

59 (34)

29 (17)

34 (20)

33 (19)

35 (20)

25 (15)

44 (25)

6 (3)

10 (6)

5 (3)

Medical history

Type I diabetes

5 (3)

3 (2)

4 (2)

Hyperthyroidism

4 (2)

2 (1)

6 (3)

Hypothyroidism

21 (12)

18 (11)

10 (6)

Addison disease

2 (1)

3 (2)

Pernicious anaemia

5 (3)

3 (2)

6 (3)

Alopecia areata

3 (2)

7 (4)

3 (2)

Duration of vitiligo (years), median (interquartile range)

7 (3–16)

5 (3–11)

7 (4–15)

Previous treatments used for vitiligo

Light therapy

28 (16)

26 (15)

37 (21)

Corticosteroid cream or ointment

80 (46)

75 (44)

80 (46)

Calcineurin inhibitor cream or ointment

51 (29)

39 (23)

56 (32)

Cosmetic camouflage

45 (26)

44 (26)

40 (23)

Other

20 (12)

15 (9)

17 (10)

Target patch location

Head and neck

53 (31)

52 (31)

56 (32)

Hands and feet

56 (32)

53 (31)

55 (31)

Rest of the body

64 (37)

64 (38)

64 (37)

Number of assessed patches

50 (29)

50 (30)

62 (35)

74 (43)

77 (46)

73 (42)

49 (28)

42 (25)

40 (23)

Target patch hypomelanotic^a

Definitely

52 (30)

46 (27)

52 (30)

Maybe or no

121 (70)

123 (73)

123 (70)

Characteristic	TCS (n = 173)	NB‐UVB (n = 169)	Combination (n = 175)
Age at randomization (years), mean (SD)	38·6 (20·0)	36·9 (18·9)	37·0 (19·1)
Age of adults at randomization (years), mean (SD); n	46·7 (15·2); 133	44·7 (14·0); 130	44·8 (14·2); 135
Age of children at randomization (years), mean (SD); n	11·7 (3·7); 40	10·8 (3·5); 39	10·6 (3·3); 40
Sex male	75 (43)	88 (52)	105 (60)
Ethnicity
White	112 (65)	114 (67)	104 (59)
Indian	13 (8)	13 (8)	10 (6)
Pakistani	12 (7)	15 (9)	27 (15)
Bangladeshi	4 (2)	4 (2)	4 (2)
Black	5 (3)	3 (2)	7 (4)
Chinese	2 (1)	1 (1)	1 (1)
Other Asian (not Chinese)	5 (3)	6 (4)	6 (3)
Mixed race	9 (5)	6 (4)	6 (3)
Other	10 (6)	7 (4)	9 (5)
Missing	1 (1)	0	1 (1)
Source of recruitment
Primary care	35 (20)	36 (21)	47 (27)
Secondary care	74 (43)	67 (40)	72 (41)
Self‐referral	64 (37)	66 (39)	56 (32)
Skin phototype
I	2 (1)	2 (1)	5 (3)
II	31 (18)	32 (19)	29 (17)
III	70 (40)	66 (39)	59 (34)
IV	29 (17)	34 (20)	33 (19)
V	35 (20)	25 (15)	44 (25)
VI	6 (3)	10 (6)	5 (3)
Medical history
Type I diabetes	5 (3)	3 (2)	4 (2)
Hyperthyroidism	4 (2)	2 (1)	6 (3)
Hypothyroidism	21 (12)	18 (11)	10 (6)
Addison disease	2 (1)	0	3 (2)
Pernicious anaemia	5 (3)	3 (2)	6 (3)
Alopecia areata	3 (2)	7 (4)	3 (2)
Duration of vitiligo (years), median (interquartile range)	7 (3–16)	5 (3–11)	7 (4–15)
Previous treatments used for vitiligo
Light therapy	28 (16)	26 (15)	37 (21)
Corticosteroid cream or ointment	80 (46)	75 (44)	80 (46)
Calcineurin inhibitor cream or ointment	51 (29)	39 (23)	56 (32)
Cosmetic camouflage	45 (26)	44 (26)	40 (23)
Other	20 (12)	15 (9)	17 (10)
Target patch location
Head and neck	53 (31)	52 (31)	56 (32)
Hands and feet	56 (32)	53 (31)	55 (31)
Rest of the body	64 (37)	64 (38)	64 (37)
Number of assessed patches
1	50 (29)	50 (30)	62 (35)
2	74 (43)	77 (46)	73 (42)
3	49 (28)	42 (25)	40 (23)
Target patch hypomelanotic^a
Definitely	52 (30)	46 (27)	52 (30)
Maybe or no	121 (70)	123 (73)	123 (70)

Table 1

Open in new tab

Baseline characteristics

Characteristic	TCS (n = 173)	NB‐UVB (n = 169)	Combination (n = 175)
Age at randomization (years), mean (SD)	38·6 (20·0)	36·9 (18·9)	37·0 (19·1)
Age of adults at randomization (years), mean (SD); n	46·7 (15·2); 133	44·7 (14·0); 130	44·8 (14·2); 135
Age of children at randomization (years), mean (SD); n	11·7 (3·7); 40	10·8 (3·5); 39	10·6 (3·3); 40
Sex male	75 (43)	88 (52)	105 (60)
Ethnicity
White	112 (65)	114 (67)	104 (59)
Indian	13 (8)	13 (8)	10 (6)
Pakistani	12 (7)	15 (9)	27 (15)
Bangladeshi	4 (2)	4 (2)	4 (2)
Black	5 (3)	3 (2)	7 (4)
Chinese	2 (1)	1 (1)	1 (1)
Other Asian (not Chinese)	5 (3)	6 (4)	6 (3)
Mixed race	9 (5)	6 (4)	6 (3)
Other	10 (6)	7 (4)	9 (5)
Missing	1 (1)	0	1 (1)
Source of recruitment
Primary care	35 (20)	36 (21)	47 (27)
Secondary care	74 (43)	67 (40)	72 (41)
Self‐referral	64 (37)	66 (39)	56 (32)
Skin phototype
I	2 (1)	2 (1)	5 (3)
II	31 (18)	32 (19)	29 (17)
III	70 (40)	66 (39)	59 (34)
IV	29 (17)	34 (20)	33 (19)
V	35 (20)	25 (15)	44 (25)
VI	6 (3)	10 (6)	5 (3)
Medical history
Type I diabetes	5 (3)	3 (2)	4 (2)
Hyperthyroidism	4 (2)	2 (1)	6 (3)
Hypothyroidism	21 (12)	18 (11)	10 (6)
Addison disease	2 (1)	0	3 (2)
Pernicious anaemia	5 (3)	3 (2)	6 (3)
Alopecia areata	3 (2)	7 (4)	3 (2)
Duration of vitiligo (years), median (interquartile range)	7 (3–16)	5 (3–11)	7 (4–15)
Previous treatments used for vitiligo
Light therapy	28 (16)	26 (15)	37 (21)
Corticosteroid cream or ointment	80 (46)	75 (44)	80 (46)
Calcineurin inhibitor cream or ointment	51 (29)	39 (23)	56 (32)
Cosmetic camouflage	45 (26)	44 (26)	40 (23)
Other	20 (12)	15 (9)	17 (10)
Target patch location
Head and neck	53 (31)	52 (31)	56 (32)
Hands and feet	56 (32)	53 (31)	55 (31)
Rest of the body	64 (37)	64 (38)	64 (37)
Number of assessed patches
1	50 (29)	50 (30)	62 (35)
2	74 (43)	77 (46)	73 (42)
3	49 (28)	42 (25)	40 (23)
Target patch hypomelanotic^a
Definitely	52 (30)	46 (27)	52 (30)
Maybe or no	121 (70)	123 (73)	123 (70)

Characteristic	TCS (n = 173)	NB‐UVB (n = 169)	Combination (n = 175)
Age at randomization (years), mean (SD)	38·6 (20·0)	36·9 (18·9)	37·0 (19·1)
Age of adults at randomization (years), mean (SD); n	46·7 (15·2); 133	44·7 (14·0); 130	44·8 (14·2); 135
Age of children at randomization (years), mean (SD); n	11·7 (3·7); 40	10·8 (3·5); 39	10·6 (3·3); 40
Sex male	75 (43)	88 (52)	105 (60)
Ethnicity
White	112 (65)	114 (67)	104 (59)
Indian	13 (8)	13 (8)	10 (6)
Pakistani	12 (7)	15 (9)	27 (15)
Bangladeshi	4 (2)	4 (2)	4 (2)
Black	5 (3)	3 (2)	7 (4)
Chinese	2 (1)	1 (1)	1 (1)
Other Asian (not Chinese)	5 (3)	6 (4)	6 (3)
Mixed race	9 (5)	6 (4)	6 (3)
Other	10 (6)	7 (4)	9 (5)
Missing	1 (1)	0	1 (1)
Source of recruitment
Primary care	35 (20)	36 (21)	47 (27)
Secondary care	74 (43)	67 (40)	72 (41)
Self‐referral	64 (37)	66 (39)	56 (32)
Skin phototype
I	2 (1)	2 (1)	5 (3)
II	31 (18)	32 (19)	29 (17)
III	70 (40)	66 (39)	59 (34)
IV	29 (17)	34 (20)	33 (19)
V	35 (20)	25 (15)	44 (25)
VI	6 (3)	10 (6)	5 (3)
Medical history
Type I diabetes	5 (3)	3 (2)	4 (2)
Hyperthyroidism	4 (2)	2 (1)	6 (3)
Hypothyroidism	21 (12)	18 (11)	10 (6)
Addison disease	2 (1)	0	3 (2)
Pernicious anaemia	5 (3)	3 (2)	6 (3)
Alopecia areata	3 (2)	7 (4)	3 (2)
Duration of vitiligo (years), median (interquartile range)	7 (3–16)	5 (3–11)	7 (4–15)
Previous treatments used for vitiligo
Light therapy	28 (16)	26 (15)	37 (21)
Corticosteroid cream or ointment	80 (46)	75 (44)	80 (46)
Calcineurin inhibitor cream or ointment	51 (29)	39 (23)	56 (32)
Cosmetic camouflage	45 (26)	44 (26)	40 (23)
Other	20 (12)	15 (9)	17 (10)
Target patch location
Head and neck	53 (31)	52 (31)	56 (32)
Hands and feet	56 (32)	53 (31)	55 (31)
Rest of the body	64 (37)	64 (38)	64 (37)
Number of assessed patches
1	50 (29)	50 (30)	62 (35)
2	74 (43)	77 (46)	73 (42)
3	49 (28)	42 (25)	40 (23)
Target patch hypomelanotic^a
Definitely	52 (30)	46 (27)	52 (30)
Maybe or no	121 (70)	123 (73)	123 (70)

The data are presented as n (%) unless otherwise indicated. NB‐UVB, narrowband ultraviolet B; TCS, topical corticosteroid. ^aIt is thought that patches that are hypomelanotic, with poorly defined borders, are more likely to be active, and therefore more responsive to treatment. Patches were assessed at the point of randomization using Wood’s lamp.

This Feature Is Available To Subscribers Only